A super drug — at a super price

Organisation: Position: Deadline Date: Location:

Sovaldi[/b], a new drug to treat hepatitis C and approved by the [b]US Food and Drug Administration[/b] in December, is a big advance, writes [s]The New York Times[/s]. When taken with one or two older drugs, Sovaldi can cure more than 80% of cases of hepatitis C in as little as 12 weeks – a higher cure rate with shorter treatment duration and fewer side effects than was previously possible.

But the $84,000 price for a 12-week course of treatment, or $1,000 a daily pill, as caused rising concern among insurers and [b]Medicaid[/b] programmes in the US. Three to four million Americans are estimated to be infected with the hepatitis C virus and over decades, infection can cause cirrhosis of the liver and liver cancer.

[s]Reuters[/s] reports that the controversy was fanned further by the developer, [b]Gilead Sciences[/b], agreeing to supply the medicine to Egypt at a 99% discount to the US price. Egypt, has the highest prevalence rate of hepatitis C in the world. The [b]World Health Organisation[/b] estimates that more than 150m worldwide are chronically infected, most of them in developing countries.

Full The New York Times report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.